Divis Laboratories Share Price
Sector: Biotechnology & Drugs
You have to be logged in to add this to Watchlist.
Login or Register
6130.40 +23.05 (0.38%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6055.3
Today’s High
6141.8
52 Week Low
3300
52 Week High
6276.2
6123.65 +16.95 (0.28%)
- 1D
- 5D
- 1M
- 3M
- 6M
- 1Y
- 5Y
- MAX
Price Range
Today’s Low
6057
Today’s High
6142.75
52 Week Low
3295.3
52 Week High
6275.85
Key Metrics
- Market Cap (In Cr) 162113.7
- Beta 0.55
- Div. Yield (%) 0.49
- P/B 11.95
- TTM P/E 72.9
- Peg Ratio 4.48
- Sector P/E 37.57
- D/E -
- Open Price 6085.6
- Prev Close 6107.35
Divis Laboratories Analysis
Price Analysis
-
1 Week10.09%
-
3 Months33.6%
-
6 Month62.23%
-
YTD56.43%
-
1 Year67.07%
Risk Meter
- 27% Low risk
- 27% Moderate risk
- 27% Balanced Risk
- 27% High risk
- 27% Extreme risk
Recos
- Strong Sell
- Sell
- Hold
- Buy
- Strong Buy
Analysts' Views
- Ratings
- Current
- 1 W Ago
- 1 M Ago
- 3 M Ago
- Strong Buy
- 3
- 2
- 2
- 3
- Buy
- 3
- 3
- 3
- 1
- Hold
- 6
- 6
- 6
- 7
- Sell
- 5
- 5
- 5
- 6
- Strong Sell
- 6
- 6
- 6
- 5
- Total
- 23
- 22
- 22
- 22
Divis Laboratories News
HDFC Asset Management Company, Divis Laboratories & others hit 52 week high today ; Do you own any?
4 min read . 15 Oct 2024National Aluminium Company, India Glycols & others hit 52 week high today ; Do you own any?
3 min read . 14 Oct 2024Divis Laboratories Financials
- INCOME
- BALANCE SHEET
- Cashflow
- Period
- 2024
- Total Revenue
- 7845
- Selling/ General/ Admin Expenses Total
- 1094
- Depreciation/ Amortization
- 378
- Other Operating Expenses Total
- 1417
- Total Operating Expense
- 6018
- Operating Income
- 1827
- Net Income Before Taxes
- 2163
- Net Income
- 1600
- Diluted Normalized EPS
- 60.27
- Period
- 2024
- Total Assets
- 15470
- Total Liabilities
- 1899
- Total Equity
- 13571
- Tangible Book Valueper Share Common Eq
- 511.06
- Period
- 2024
- Cashfrom Operating Activities
- 1261
- Cashfrom Investing Activities
- -269
- Cashfrom Financing Activities
- -799
- Net Changein Cash
- 193
- Period
- 2023
- Total Revenue
- 7767.51
- Selling/ General/ Admin Expenses Total
- 1654.4
- Depreciation/ Amortization
- 343.18
- Total Operating Expense
- 5741.74
- Operating Income
- 2025.77
- Net Income Before Taxes
- 2368.63
- Net Income
- 1823.38
- Diluted Normalized EPS
- 68.72
- Period
- 2023
- Total Assets
- 14438.77
- Total Liabilities
- 1671.68
- Total Equity
- 12767.09
- Tangible Book Valueper Share Common Eq
- 480.73
- Period
- 2023
- Cashfrom Operating Activities
- 2459.73
- Cashfrom Investing Activities
- -2707.62
- Cashfrom Financing Activities
- -797.17
- Net Changein Cash
- -1045.06
- Period
- 2022
- Total Revenue
- 8959.83
- Selling/ General/ Admin Expenses Total
- 1541.48
- Depreciation/ Amortization
- 311.51
- Total Operating Expense
- 5387.35
- Operating Income
- 3572.48
- Net Income Before Taxes
- 3683.5
- Net Income
- 2960.45
- Diluted Normalized EPS
- 111.58
- Period
- 2022
- Total Assets
- 13374.71
- Total Liabilities
- 1646.53
- Total Equity
- 11728.18
- Tangible Book Valueper Share Common Eq
- 441.51
- Period
- 2022
- Cashfrom Operating Activities
- 1911.8
- Cashfrom Investing Activities
- -2194.92
- Cashfrom Financing Activities
- -532.44
- Net Changein Cash
- -815.56
- Period
- 2021
- Total Revenue
- 6969.4
- Selling/ General/ Admin Expenses Total
- 1306
- Depreciation/ Amortization
- 255.59
- Total Operating Expense
- 4354.71
- Operating Income
- 2614.69
- Net Income Before Taxes
- 2666.04
- Net Income
- 1984.29
- Diluted Normalized EPS
- 74.91
- Period
- 2021
- Total Assets
- 10774.07
- Total Liabilities
- 1479.46
- Total Equity
- 9294.61
- Tangible Book Valueper Share Common Eq
- 349.93
- Period
- 2021
- Cashfrom Operating Activities
- 1946.93
- Cashfrom Investing Activities
- 75.13
- Cashfrom Financing Activities
- -34.89
- Net Changein Cash
- 1987.17
- Period
- 2020
- Total Revenue
- 5394.42
- Selling/ General/ Admin Expenses Total
- 1061.8
- Depreciation/ Amortization
- 186.24
- Total Operating Expense
- 3754.2
- Operating Income
- 1640.22
- Net Income Before Taxes
- 1819.46
- Net Income
- 1376.54
- Diluted Normalized EPS
- 51.95
- Period
- 2020
- Total Assets
- 8535.7
- Total Liabilities
- 1225.78
- Total Equity
- 7309.92
- Tangible Book Valueper Share Common Eq
- 275.22
- Period
- 2020
- Cashfrom Operating Activities
- 1215.94
- Cashfrom Investing Activities
- -83.47
- Cashfrom Financing Activities
- -1091.42
- Net Changein Cash
- 41.05
- Period
- 2019
- Total Revenue
- 4946.26
- Selling/ General/ Admin Expenses Total
- 881.55
- Depreciation/ Amortization
- 168.9
- Total Operating Expense
- 3240.75
- Operating Income
- 1705.51
- Net Income Before Taxes
- 1855.07
- Net Income
- 1352.74
- Diluted Normalized EPS
- 50.99
- Period
- 2019
- Total Assets
- 8038.25
- Total Liabilities
- 1081.1
- Total Equity
- 6957.15
- Tangible Book Valueper Share Common Eq
- 261.92
- Period
- 2019
- Cashfrom Operating Activities
- 954.3
- Cashfrom Investing Activities
- -685.4
- Cashfrom Financing Activities
- -245.94
- Net Changein Cash
- 22.96
- Period
- 2018
- Total Revenue
- 3912.78
- Selling/ General/ Admin Expenses Total
- 757.07
- Depreciation/ Amortization
- 142.49
- Total Operating Expense
- 2787.3
- Operating Income
- 1125.48
- Net Income Before Taxes
- 1231.33
- Net Income
- 877.01
- Diluted Normalized EPS
- 33.2
- Period
- 2018
- Total Assets
- 6785.85
- Total Liabilities
- 861.05
- Total Equity
- 5924.8
- Tangible Book Valueper Share Common Eq
- 222.94
- Period
- 2018
- Cashfrom Operating Activities
- 775.86
- Cashfrom Investing Activities
- -478.3
- Cashfrom Financing Activities
- -314.16
- Net Changein Cash
- -16.6
- Period
- 2024-06-30
- Total Revenue
- 2118
- Selling/ General/ Admin Expenses Total
- 292
- Depreciation/ Amortization
- 97
- Other Operating Expenses Total
- 350
- Total Operating Expense
- 1592
- Operating Income
- 526
- Net Income Before Taxes
- 604
- Net Income
- 430
- Diluted Normalized EPS
- 16.2
- Period
- 2024-06-30
- Period
- 2024-06-30
- Period
- 2024-03-31
- Total Revenue
- 2303
- Selling/ General/ Admin Expenses Total
- 297
- Depreciation/ Amortization
- 95
- Other Operating Expenses Total
- 373
- Total Operating Expense
- 1667
- Operating Income
- 636
- Net Income Before Taxes
- 713
- Net Income
- 538
- Diluted Normalized EPS
- 20.25
- Period
- 2024-03-31
- Total Assets
- 15470
- Total Liabilities
- 1899
- Total Equity
- 13571
- Tangible Book Valueper Share Common Eq
- 511.06
- Period
- 2024-03-31
- Cashfrom Operating Activities
- 1261
- Cashfrom Investing Activities
- -269
- Cashfrom Financing Activities
- -799
- Net Changein Cash
- 193
- Period
- 2023-12-31
- Total Revenue
- 1855
- Selling/ General/ Admin Expenses Total
- 268
- Depreciation/ Amortization
- 95
- Other Operating Expenses Total
- 369
- Total Operating Expense
- 1461
- Operating Income
- 394
- Net Income Before Taxes
- 489
- Net Income
- 358
- Diluted Normalized EPS
- 13.5
- Period
- 2023-12-31
- Period
- 2023-12-31
- Period
- 2023-09-30
- Total Revenue
- 1909
- Selling/ General/ Admin Expenses Total
- 266
- Depreciation/ Amortization
- 95
- Other Operating Expenses Total
- 354
- Total Operating Expense
- 1525
- Operating Income
- 384
- Net Income Before Taxes
- 469
- Net Income
- 348
- Diluted Normalized EPS
- 13.11
- Period
- 2023-09-30
- Total Assets
- 14283
- Total Liabilities
- 1606
- Total Equity
- 12677
- Tangible Book Valueper Share Common Eq
- 477.42
- Period
- 2023-09-30
- Cashfrom Operating Activities
- 539
- Cashfrom Investing Activities
- 122
- Cashfrom Financing Activities
- -798
- Net Changein Cash
- -137
- Period
- 2023-06-30
- Total Revenue
- 1778
- Selling/ General/ Admin Expenses Total
- 263
- Depreciation/ Amortization
- 93
- Other Operating Expenses Total
- 323
- Total Operating Expense
- 1367
- Operating Income
- 411
- Net Income Before Taxes
- 492
- Net Income
- 356
- Diluted Normalized EPS
- 13.41
- Period
- 2023-06-30
- Period
- 2023-06-30
- Period
- 2023-03-31
- Total Revenue
- 1950.77
- Selling/ General/ Admin Expenses Total
- 257.64
- Depreciation/ Amortization
- 87.02
- Other Operating Expenses Total
- 373.75
- Total Operating Expense
- 1545.99
- Operating Income
- 404.78
- Net Income Before Taxes
- 466.48
- Net Income
- 320.97
- Diluted Normalized EPS
- 12.09
- Period
- 2023-03-31
- Total Assets
- 14438.77
- Total Liabilities
- 1671.68
- Total Equity
- 12767.09
- Tangible Book Valueper Share Common Eq
- 480.73
- Period
- 2023-03-31
- Cashfrom Operating Activities
- 2459.73
- Cashfrom Investing Activities
- -2707.62
- Cashfrom Financing Activities
- -797.17
- Net Changein Cash
- -1045.06
- Period
- 2022-12-31
- Total Revenue
- 1707.68
- Selling/ General/ Admin Expenses Total
- 238.88
- Depreciation/ Amortization
- 86.77
- Other Operating Expenses Total
- 320.97
- Total Operating Expense
- 1386.17
- Operating Income
- 321.51
- Net Income Before Taxes
- 435.63
- Net Income
- 306.8
- Diluted Normalized EPS
- 11.56
- Period
- 2022-12-31
- Period
- 2022-12-31
Forecast
Income Sheet (In Cr)
Net Income Vs Revenue
Returns Metrics (In Cr)
ROA Vs ROE
Forecast
Balance Sheet
Asset vs Liability
Forecast
Cash Flow
Operating vs Investing
Divis Laboratories Technical
Moving Average
SMA
- 5 Day5965.75
- 10 Day5695.05
- 20 Day5563.25
- 50 Day5206.57
- 100 Day4846.34
- 300 Day4280.84
Divis Laboratories Peers
- Price
- Ratio
- Name
- Latest Price
- Change
- % Change
- 52W High
- 52W Low
- Mkt. Cap
- Sun Pharmaceutical Industries
- 1896.35
- -1.15
- -0.06
- 1960.2
- 1069
- 454997.89
- Divis Laboratories
- 6130.4
- 23.05
- 0.38
- 6276.2
- 3300
- 162742.86
- Cipla
- 1563.8
- -7.65
- -0.49
- 1702
- 1132
- 126260.43
- Torrent Pharmaceuticals
- 3505.7
- 8.3
- 0.24
- 3589.95
- 1822.8
- 118653.92
- Dr Reddys Laboratories
- 6709.6
- 91.7
- 1.39
- 7101
- 5212.1
- 111733.95
- Name
- P/E (X)
- P/B (X)
- ROE %
- OPM
- Sun Pharmaceutical Industries
- 45.76
- 7.2
- 11.27
- 14.23
- Divis Laboratories
- 102.93
- 12.16
- 18.97
- 26.38
- Cipla
- 29.73
- 4.83
- 13.5
- 12.66
- Torrent Pharmaceuticals
- 73.67
- 17.23
- 20.64
- 13.18
- Dr Reddys Laboratories
- 20.16
- 3.93
- 16.73
- 14.63
Divis Laboratories Shareholding
Shareholding Pattern
Shareholding Trend
Shareholding(%) v/s Date
Corporate Actions
- Board Meeting
- AGM
- Dividends
- Bonus
- Split
- Rights
- Meeting Date
- Purpose
- 03-Aug-24
- Quarterly Results
- 25-May-24
- Audited Results & Dividend
- 10-Feb-24
- Quarterly Results
- 06-Nov-23
- Quarterly Results
- 14-Aug-23
- Quarterly Results
- 20-May-23
- Audited Results & Final Dividend
- 03-Feb-23
- Quarterly Results
- 07-Nov-22
- Quarterly Results
- 12-Aug-22
- Quarterly Results
- 23-May-22
- Audited Results & Dividend
- Meeting Date
- Announced on
- Purpose
- 06-Apr-24
- 04-Mar-24
- POM
- 28-Aug-23
- 20-May-23
- AGM
- 22-Aug-22
- 04-Jul-22
- AGM
- 28-Mar-22
- 24-Feb-22
- POM
- 30-Aug-21
- 02-Aug-21
- AGM
- Announced on
- Record Date
- Ex-Dividend
- Dividend Value
- 27-May-24
- 02-Aug-24
- 02-Aug-24
- 30
- 22-May-23
- 11-Aug-23
- 11-Aug-23
- 30
- 23-May-22
- 12-Aug-22
- 11-Aug-22
- 30
- 31-May-21
- -
- 17-Aug-21
- 20